Electrophysiological features and prognosis of Guillain-Barré syndrome in Israel: A single-center's 20 years' experience

We previously reported on 40 patients with Guillain-Barré syndrome (GBS) identified 1999–2005 at our center, and showed that a higher proportion had an axonal pattern, compared to Europe and North America. Retrospective chart review of 100 adult patients with GBS between 2006 and 2018 at Shamir Medi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the neurological sciences 2020-10, Vol.417, p.117074-117074, Article 117074
Hauptverfasser: Kenan, Gilad, Kushnir, Mark, Leonov, Yuval, Ilgiyaev, Eduard, Aroesty, Rina, Bhonkar, Sarah, Kimiagar, Itzhak, Armon, Carmel
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 117074
container_issue
container_start_page 117074
container_title Journal of the neurological sciences
container_volume 417
creator Kenan, Gilad
Kushnir, Mark
Leonov, Yuval
Ilgiyaev, Eduard
Aroesty, Rina
Bhonkar, Sarah
Kimiagar, Itzhak
Armon, Carmel
description We previously reported on 40 patients with Guillain-Barré syndrome (GBS) identified 1999–2005 at our center, and showed that a higher proportion had an axonal pattern, compared to Europe and North America. Retrospective chart review of 100 adult patients with GBS between 2006 and 2018 at Shamir Medical Center. 46.8% of those with an abnormal EMG had an axonal pattern. Of the 60 patients who presented with mild disease (defined as Hughes score 1–2), walking deteriorated in 35 (58%, considering any worsening of Hughes score). 20 patients (33%) lost the ability to walk independently (Hughes score 3), 8 reached a point they could not walk (Hughes 4), and 2 needed mechanical ventilation. Ninety-four of 100 patients (94%) were treated with intravenous immunoglobulins (IVIg). Using ECG monitoring and DVT prophylaxis, IVIg-related adverse reactions were rare. This study demonstrated a higher proportion of axonal GBS patients in Israel, compared to European and North American patients, replicating the findings in the 1999–2005 patients. Due to the progressive nature of the disease, with more than half of patients presenting with mild disease deteriorating and needing inpatient rehabilitation - we advocate initiation of treatment once a clinical diagnosis of GBS is made. •20 years' experience with GBS in a single center in Israel•Consistently higher axonal pattern in Israel than in USA or Europe•Treatment of mild patients supported•Low frequency of adverse events with DVT prophylaxis and ECG monitoring
doi_str_mv 10.1016/j.jns.2020.117074
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2431827162</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022510X20304111</els_id><sourcerecordid>2431827162</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-f926588bdb3abdbd2eb4f466b7a6b40a6b0f954eaff98057db5c9d4f7e70b3443</originalsourceid><addsrcrecordid>eNp9kMFu1DAURS0EotPCB7BB3pVNBttxYgdWpWpLpUrdFImd5TjPg0cZe_BLKvJJfAc_hsuULru5T0-690r3EPKOszVnvP24XW8jrgUT5eeKKfmCrLhWumq0rl-SFWNCVA1n34_IMeKWMdZq3b0mR7VQrVa8W5HlYgQ35bT_sWBIY9oEZ0fqwU5zBqQ2DnSf0yYmDEiTp1dzGEcbYvXF5vznN8UlDjntgIZIrzFbGD_RM4ohbkaoHMQJ8ilSwegCNuMphV97yAGigzfklbcjwtvHe0K-XV7cnX-tbm6vrs_PbipXN_VU-U60ZU4_9LUtMgjopZdt2yvb9pIVYb5rJFjvO80aNfSN6wbpFSjW11LWJ-TDobfs-DkDTmYX0EFZESHNaISsuRaKt6JY-cHqckLM4M0-h53Ni-HMPBA3W1OImwfi5kC8ZN4_1s_9DoanxH_ExfD5YIAy8j5ANuj-ARhCLujNkMIz9X8Bg1OT7A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2431827162</pqid></control><display><type>article</type><title>Electrophysiological features and prognosis of Guillain-Barré syndrome in Israel: A single-center's 20 years' experience</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Kenan, Gilad ; Kushnir, Mark ; Leonov, Yuval ; Ilgiyaev, Eduard ; Aroesty, Rina ; Bhonkar, Sarah ; Kimiagar, Itzhak ; Armon, Carmel</creator><creatorcontrib>Kenan, Gilad ; Kushnir, Mark ; Leonov, Yuval ; Ilgiyaev, Eduard ; Aroesty, Rina ; Bhonkar, Sarah ; Kimiagar, Itzhak ; Armon, Carmel</creatorcontrib><description>We previously reported on 40 patients with Guillain-Barré syndrome (GBS) identified 1999–2005 at our center, and showed that a higher proportion had an axonal pattern, compared to Europe and North America. Retrospective chart review of 100 adult patients with GBS between 2006 and 2018 at Shamir Medical Center. 46.8% of those with an abnormal EMG had an axonal pattern. Of the 60 patients who presented with mild disease (defined as Hughes score 1–2), walking deteriorated in 35 (58%, considering any worsening of Hughes score). 20 patients (33%) lost the ability to walk independently (Hughes score 3), 8 reached a point they could not walk (Hughes 4), and 2 needed mechanical ventilation. Ninety-four of 100 patients (94%) were treated with intravenous immunoglobulins (IVIg). Using ECG monitoring and DVT prophylaxis, IVIg-related adverse reactions were rare. This study demonstrated a higher proportion of axonal GBS patients in Israel, compared to European and North American patients, replicating the findings in the 1999–2005 patients. Due to the progressive nature of the disease, with more than half of patients presenting with mild disease deteriorating and needing inpatient rehabilitation - we advocate initiation of treatment once a clinical diagnosis of GBS is made. •20 years' experience with GBS in a single center in Israel•Consistently higher axonal pattern in Israel than in USA or Europe•Treatment of mild patients supported•Low frequency of adverse events with DVT prophylaxis and ECG monitoring</description><identifier>ISSN: 0022-510X</identifier><identifier>EISSN: 1878-5883</identifier><identifier>DOI: 10.1016/j.jns.2020.117074</identifier><identifier>PMID: 32768719</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adult ; Axonal variant ; Demyelinating variant ; Europe ; GBS ; Guillain-Barre Syndrome - diagnosis ; Guillain-Barre Syndrome - epidemiology ; Guillain-Barre Syndrome - therapy ; Humans ; Immunoglobulins, Intravenous - therapeutic use ; Israel - epidemiology ; IVIg safety ; North America ; Outcomes ; Prognosis ; Retrospective Studies</subject><ispartof>Journal of the neurological sciences, 2020-10, Vol.417, p.117074-117074, Article 117074</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright © 2020 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c353t-f926588bdb3abdbd2eb4f466b7a6b40a6b0f954eaff98057db5c9d4f7e70b3443</citedby><cites>FETCH-LOGICAL-c353t-f926588bdb3abdbd2eb4f466b7a6b40a6b0f954eaff98057db5c9d4f7e70b3443</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jns.2020.117074$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32768719$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kenan, Gilad</creatorcontrib><creatorcontrib>Kushnir, Mark</creatorcontrib><creatorcontrib>Leonov, Yuval</creatorcontrib><creatorcontrib>Ilgiyaev, Eduard</creatorcontrib><creatorcontrib>Aroesty, Rina</creatorcontrib><creatorcontrib>Bhonkar, Sarah</creatorcontrib><creatorcontrib>Kimiagar, Itzhak</creatorcontrib><creatorcontrib>Armon, Carmel</creatorcontrib><title>Electrophysiological features and prognosis of Guillain-Barré syndrome in Israel: A single-center's 20 years' experience</title><title>Journal of the neurological sciences</title><addtitle>J Neurol Sci</addtitle><description>We previously reported on 40 patients with Guillain-Barré syndrome (GBS) identified 1999–2005 at our center, and showed that a higher proportion had an axonal pattern, compared to Europe and North America. Retrospective chart review of 100 adult patients with GBS between 2006 and 2018 at Shamir Medical Center. 46.8% of those with an abnormal EMG had an axonal pattern. Of the 60 patients who presented with mild disease (defined as Hughes score 1–2), walking deteriorated in 35 (58%, considering any worsening of Hughes score). 20 patients (33%) lost the ability to walk independently (Hughes score 3), 8 reached a point they could not walk (Hughes 4), and 2 needed mechanical ventilation. Ninety-four of 100 patients (94%) were treated with intravenous immunoglobulins (IVIg). Using ECG monitoring and DVT prophylaxis, IVIg-related adverse reactions were rare. This study demonstrated a higher proportion of axonal GBS patients in Israel, compared to European and North American patients, replicating the findings in the 1999–2005 patients. Due to the progressive nature of the disease, with more than half of patients presenting with mild disease deteriorating and needing inpatient rehabilitation - we advocate initiation of treatment once a clinical diagnosis of GBS is made. •20 years' experience with GBS in a single center in Israel•Consistently higher axonal pattern in Israel than in USA or Europe•Treatment of mild patients supported•Low frequency of adverse events with DVT prophylaxis and ECG monitoring</description><subject>Adult</subject><subject>Axonal variant</subject><subject>Demyelinating variant</subject><subject>Europe</subject><subject>GBS</subject><subject>Guillain-Barre Syndrome - diagnosis</subject><subject>Guillain-Barre Syndrome - epidemiology</subject><subject>Guillain-Barre Syndrome - therapy</subject><subject>Humans</subject><subject>Immunoglobulins, Intravenous - therapeutic use</subject><subject>Israel - epidemiology</subject><subject>IVIg safety</subject><subject>North America</subject><subject>Outcomes</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><issn>0022-510X</issn><issn>1878-5883</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMFu1DAURS0EotPCB7BB3pVNBttxYgdWpWpLpUrdFImd5TjPg0cZe_BLKvJJfAc_hsuULru5T0-690r3EPKOszVnvP24XW8jrgUT5eeKKfmCrLhWumq0rl-SFWNCVA1n34_IMeKWMdZq3b0mR7VQrVa8W5HlYgQ35bT_sWBIY9oEZ0fqwU5zBqQ2DnSf0yYmDEiTp1dzGEcbYvXF5vznN8UlDjntgIZIrzFbGD_RM4ohbkaoHMQJ8ilSwegCNuMphV97yAGigzfklbcjwtvHe0K-XV7cnX-tbm6vrs_PbipXN_VU-U60ZU4_9LUtMgjopZdt2yvb9pIVYb5rJFjvO80aNfSN6wbpFSjW11LWJ-TDobfs-DkDTmYX0EFZESHNaISsuRaKt6JY-cHqckLM4M0-h53Ni-HMPBA3W1OImwfi5kC8ZN4_1s_9DoanxH_ExfD5YIAy8j5ANuj-ARhCLujNkMIz9X8Bg1OT7A</recordid><startdate>20201015</startdate><enddate>20201015</enddate><creator>Kenan, Gilad</creator><creator>Kushnir, Mark</creator><creator>Leonov, Yuval</creator><creator>Ilgiyaev, Eduard</creator><creator>Aroesty, Rina</creator><creator>Bhonkar, Sarah</creator><creator>Kimiagar, Itzhak</creator><creator>Armon, Carmel</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20201015</creationdate><title>Electrophysiological features and prognosis of Guillain-Barré syndrome in Israel: A single-center's 20 years' experience</title><author>Kenan, Gilad ; Kushnir, Mark ; Leonov, Yuval ; Ilgiyaev, Eduard ; Aroesty, Rina ; Bhonkar, Sarah ; Kimiagar, Itzhak ; Armon, Carmel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-f926588bdb3abdbd2eb4f466b7a6b40a6b0f954eaff98057db5c9d4f7e70b3443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Axonal variant</topic><topic>Demyelinating variant</topic><topic>Europe</topic><topic>GBS</topic><topic>Guillain-Barre Syndrome - diagnosis</topic><topic>Guillain-Barre Syndrome - epidemiology</topic><topic>Guillain-Barre Syndrome - therapy</topic><topic>Humans</topic><topic>Immunoglobulins, Intravenous - therapeutic use</topic><topic>Israel - epidemiology</topic><topic>IVIg safety</topic><topic>North America</topic><topic>Outcomes</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kenan, Gilad</creatorcontrib><creatorcontrib>Kushnir, Mark</creatorcontrib><creatorcontrib>Leonov, Yuval</creatorcontrib><creatorcontrib>Ilgiyaev, Eduard</creatorcontrib><creatorcontrib>Aroesty, Rina</creatorcontrib><creatorcontrib>Bhonkar, Sarah</creatorcontrib><creatorcontrib>Kimiagar, Itzhak</creatorcontrib><creatorcontrib>Armon, Carmel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the neurological sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kenan, Gilad</au><au>Kushnir, Mark</au><au>Leonov, Yuval</au><au>Ilgiyaev, Eduard</au><au>Aroesty, Rina</au><au>Bhonkar, Sarah</au><au>Kimiagar, Itzhak</au><au>Armon, Carmel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Electrophysiological features and prognosis of Guillain-Barré syndrome in Israel: A single-center's 20 years' experience</atitle><jtitle>Journal of the neurological sciences</jtitle><addtitle>J Neurol Sci</addtitle><date>2020-10-15</date><risdate>2020</risdate><volume>417</volume><spage>117074</spage><epage>117074</epage><pages>117074-117074</pages><artnum>117074</artnum><issn>0022-510X</issn><eissn>1878-5883</eissn><abstract>We previously reported on 40 patients with Guillain-Barré syndrome (GBS) identified 1999–2005 at our center, and showed that a higher proportion had an axonal pattern, compared to Europe and North America. Retrospective chart review of 100 adult patients with GBS between 2006 and 2018 at Shamir Medical Center. 46.8% of those with an abnormal EMG had an axonal pattern. Of the 60 patients who presented with mild disease (defined as Hughes score 1–2), walking deteriorated in 35 (58%, considering any worsening of Hughes score). 20 patients (33%) lost the ability to walk independently (Hughes score 3), 8 reached a point they could not walk (Hughes 4), and 2 needed mechanical ventilation. Ninety-four of 100 patients (94%) were treated with intravenous immunoglobulins (IVIg). Using ECG monitoring and DVT prophylaxis, IVIg-related adverse reactions were rare. This study demonstrated a higher proportion of axonal GBS patients in Israel, compared to European and North American patients, replicating the findings in the 1999–2005 patients. Due to the progressive nature of the disease, with more than half of patients presenting with mild disease deteriorating and needing inpatient rehabilitation - we advocate initiation of treatment once a clinical diagnosis of GBS is made. •20 years' experience with GBS in a single center in Israel•Consistently higher axonal pattern in Israel than in USA or Europe•Treatment of mild patients supported•Low frequency of adverse events with DVT prophylaxis and ECG monitoring</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>32768719</pmid><doi>10.1016/j.jns.2020.117074</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-510X
ispartof Journal of the neurological sciences, 2020-10, Vol.417, p.117074-117074, Article 117074
issn 0022-510X
1878-5883
language eng
recordid cdi_proquest_miscellaneous_2431827162
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Adult
Axonal variant
Demyelinating variant
Europe
GBS
Guillain-Barre Syndrome - diagnosis
Guillain-Barre Syndrome - epidemiology
Guillain-Barre Syndrome - therapy
Humans
Immunoglobulins, Intravenous - therapeutic use
Israel - epidemiology
IVIg safety
North America
Outcomes
Prognosis
Retrospective Studies
title Electrophysiological features and prognosis of Guillain-Barré syndrome in Israel: A single-center's 20 years' experience
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T01%3A15%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Electrophysiological%20features%20and%20prognosis%20of%20Guillain-Barr%C3%A9%20syndrome%20in%20Israel:%20A%20single-center's%2020%20years'%20experience&rft.jtitle=Journal%20of%20the%20neurological%20sciences&rft.au=Kenan,%20Gilad&rft.date=2020-10-15&rft.volume=417&rft.spage=117074&rft.epage=117074&rft.pages=117074-117074&rft.artnum=117074&rft.issn=0022-510X&rft.eissn=1878-5883&rft_id=info:doi/10.1016/j.jns.2020.117074&rft_dat=%3Cproquest_cross%3E2431827162%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2431827162&rft_id=info:pmid/32768719&rft_els_id=S0022510X20304111&rfr_iscdi=true